Solasia Pharma KK (JP:4597) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Solasia Pharma K.K. is advancing negotiations with several Chinese pharmaceutical companies for the out-licensing of its drug DARVIAS (SP-02) in China, with an updated expectation to conclude an agreement by the end of December 2024. The delay follows a recent confirmation from Chinese authorities regarding clinical trial designs for DARVIAS’s New Drug Application (NDA) in China. This revised timeline is not anticipated to affect the company’s consolidated financial forecast for the fiscal year 2024.
For further insights into JP:4597 stock, check out TipRanks’ Stock Analysis page.
